Key Clinical Takeaways Study Design & Population: This rigorously conducted, double-blind, randomised controlled trial enrolled 17,604 patients across 41 countries
Jun 07, 2026, 17:30 ET CagriSema, a once-weekly investigational treatment that combines a novel amylin analog with a GLP-1 receptor agonist (RA), achieved significant reductions in HbA 1c and bodyweight versus comparators across three phase 3 trials in adults with type 2 diabetes (T2D) 1-3 Data from the REIMAGINE clinical development program, a series of phase 3 trials evaluating once-weekly CagriSema in adults with T2D across various stages of their disease, were presented at an ADA symposium 1-3 Novo Nordisk continues to demonstrate pioneering leadership and scientific innovation through advancing diabetes research PLAINSBORO, N.J
When placed head-to-head, people using Mounjaro lost approximately 20% of their body weight compared to 14% with Wegovy over 72 weeks
The SURMOUNT trials tested specific titration speeds and found that slower escalation significantly reduced gastrointestinal side effects
Maintaining Weight Loss Progress One common concern is whether illness will derail weight loss progress